Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the total outgoings by the health service on additional medicine spending over the Spending Review period.

In relation to the recently announced plans to increase the standard cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE), costs will start smaller but will increase over time as NICE approves more life improving and life-saving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. The final costs will depend on which medicines NICE recommends and the actual uptake of these.

We have no plans to publish an impact assessment or details of the modelling which led to this estimated figure. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences without taking essential funding from our frontline NHS services.